News and Announcements
CannPal to present at the 2019 Asian Hemp Investment Summit
- Published June 26, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- CannPal is presenting at the 2019 Asian Hemp Industry Investment Summit at the Kerry Hotel in Hong Kong on June 28th 2019
- Managing Director, Layton Mills, will be presenting on the Company’s progress and the opportunity for cannabinoids in the animal health market in Asia
- Mr Mills’s presentation is attached to this release.
Animal health company CannPal Animal Therapeutics Limited (ASX:CP1) (“CannPal” or “the Company”) is pleased to attach a presentation that will be delivered by CannPal Managing Director, Mr Layton Mills, at the 2019 Asian Hemp Industry Investment Summit at the Kerry Hotel in Hong Kong on June 28th 2019.
The purpose of the summit is to bring together cannabis industry leaders from all over the world, including expert groups on cannabis legislation in various countries, investment groups, and medical scientific research experts, to support the development of the Asian cannabis industry.
The forum is being co-hosted by the CBDG-Cannabis Industrial Fund alongside Arcview Group. The Arcview Investor Network includes more than 600 accredited investors who have put more than US$190 million behind 175 companies since inception.
About CannPal Animal Therapeutics
CannPal Animal Therapeutics Limited (ASX: CP1) is a pharmaceutical-focused animal health Company researching the benefits of medical cannabis for companion animals. CannPal is researching and developing medicines derived from cannabinoids to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.
CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and health markets by developing innovate therapeutics derived from the cannabis plant. The Company is working closely with regulatory authorities and veterinary research organisations conducting clinical trials to commercialise therapeutic products that will meet regulatory approval and support the health and well-being of companion animals.
Company Updates
Forget Startups: Why Magnetic Alliance is Betting on “Boring” Mid-Market Turnarounds
While Australia’s venture capital scene spent years chasing unprofitable tech startups and speculative high-growth plays, Mark Lim was quietly taking a radically different path. The Managing Partner of Magnetic Alliance Capital sees the nation’s richest investment opportunities hiding in plain sight: inside thousands of unglamorous, profitable, but operationally sluggish mid-market businesses. Speaking on Wholesale Investor’s […]
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Backed By Leading Investment Groups and Family Offices
